Adding Chemotherapy for a Patient Receiving ADT + an ARPI

Opinion
Video

Evan Y. Yu, MD, discusses how adding chemotherapy to a doublet regimen for metastatic hormone-sensitive prostate cancer may be considered on an as-needed basis, particularly for patients with high disease burden or rapid progression, while carefully weighing the potential benefits and risks of intensifying therapy.

Recent Videos
4 experts are featured in this series.
1 expert in this video
4 experts are featured in this series.
3 experts are featured in this series.
Related Content